Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Braga, Portugal Clinical Trials

A listing of Braga, Portugal clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

The XENERA -1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Phase

1.97 miles

Learn More »

Safety Tolerability and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)

The purpose of this study is to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Phase

9.48 miles

Learn More »

An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's Disease

This is an investigational study, also known as LATTICE, of the experimental medication BMS-986165 in patients with moderate to severe Crohn's Disease, a chronic bowel disease that causes severe inflammation of the digestive tract.

Phase

9.48 miles

Learn More »

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

This is the new concept of "conservative iron chelation". We recently demonstrated (for the first time) the feasibility, efficacy and acceptability of the conservative iron chelation approach in pilot translational studies in Parkinson's disease with a prototype drug: deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) (in the FAIR-PARK-I project led by the applicant and funded ...

Phase

9.96 miles

Learn More »

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Investigational Medicinal Products (IMPs) will be trastuzumab and pertuzumab, carboplatin, and docetaxel, as well as all endocrine therapy drugs to be administered according to HR status (hormone receptor). For cohort C, trastuzumab SC (subcutaneous) and pertuzumab IV will be IMPs until a maximum of 18 cycles. Patients will be randomly ...

Phase

9.96 miles

Learn More »